ARTICLES BY ERIC LANGER
-
![iStock-517894805]( "Cell And Gene Therapy Bioprocessing: Hiring And Capacity Crunch On The Horizon")
Cell And Gene Therapy Bioprocessing: Hiring And Capacity Crunch On The Horizon5/21/2020With a very healthy R&D pipeline of cell and gene therapies, we can expect multiple blockbuster products and various “orphan” niche products to be launched annually in coming years. As a result, the industry is heading for a capacity crunch.
-
![Bioprocessing Trends To Watch In 2018]( "Bioprocessing Trends To Watch In 2018")
Bioprocessing Trends To Watch In 201812/6/2017The current situation in biopharma is exciting, with new technologies, biosimilars, cellular and gene therapies, and opportunities in emerging markets. And these innovative platforms are going to continue to need improved manufacturing technologies in the future.
-
Change On The Horizon For Biomanufacturing1/26/2012
A leading indicator as to where the global bio industry is headed, geographically, is where its global vendors are setting up shop. In our 8th Annual Report and Survey of Biopharmaceutical Manufacturing, along with 352 biomanufacturers, we also surveyed 186 suppliers to the industry. By Eric Langer, president and managing partner, BioPlan Associates, Inc.
Eric Langer
Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD, in 1989. He is editor of numerous studies, including Biopharmaceutical Technology in China, Advances in Large-scale Biopharmaceutical Manufacturing, and many other industry reports. You can reach him at elanger@bioplanassociates.com or 301-921-5979.